Skip to main content
SpringerLink
Log in

CNS Adverse Events Associated With Antimalarial Agents

Fact or Fiction?

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

CNS adverse drug events are dramatic, and case reports have influenced clinical opinion on the use of antimalarials. Malaria also causes CNS symptoms, thus establishing causality is difficult.

CNS events are associated with the quinoline and artemisinin derivatives. Chloroquine, once considered too toxic for humans, has been the antimalarial of choice for 40 years. While a range of serious CNS effects have been documented during chloroquine therapy, the incidence is unclear (extrapyramidal symptoms occur with an incidence of 1 in 5000). Amodiaquine has a higher incidence of mild CNS effects than chloroquine. Mefloquine therapy causes dose-related transient dizziness. Serious CNS events during mefloquine therapy occur in 1: 1200 Asians and 1: 200 Caucasians/Africans. Risk factors include dosage, concomitant drug use/interactions, previous history of a CNS event and disease severity. Retreatment (within a month) increases the risk in Asians 7-fold. Studies indicate that the frequency of serious CNS events with mefloquine prophylaxis (1: 10 000) is similar to that with chloroquine (1: 13 600). Quinine causes cinchonism at standard therapeutic doses. High-tone hearing loss occurs, but irreversible auditory or ocular effects are very rare.

The artemisinin derivatives are associated with dose-dependent brain lesions in rodent, canine and nonhuman primates. At low doses, histological injury has been demonstrated, without clinical neurological signs. No significant toxicity has been reported in humans. Other antimalarial drugs are seldom associated with CNS adverse events.

Data do not suggest a need to diminish the correct use of the quinoline derivatives. Irreversible effects are extremely rare and usually associated with overdosing or prior history of a serious CNS event. Concomitant therapeutic use of 2 drugs from the same family, or retreatment with the same drug, should be avoided. Onset of drug-associated serious CNS events requires drug discontinuation and future avoidance of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. CIOMS International reporting of adverse drug reactions. CIOMS Working Group Report. Geneva: World Health Organization, 1987

  2. World Health Organization. The role of artemisinin and its derivatives in the current treatment of malaria (1994–1995). WHO/MAL/94.1067. Geneva: World Health Organization, 1994

    Google Scholar 

  3. Jaeger A, Sauder P, Kopferschmitt J, et al. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol 1987; 2: 242–73

    CAS  Google Scholar 

  4. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963; 12: 121–8

    PubMed  CAS  Google Scholar 

  5. Frisk Holmberg M, Bergqvist Y, Domeij-Niberg B, et al. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther 1979; 25: 345–50

    PubMed  CAS  Google Scholar 

  6. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341: 1299–303

    Article  PubMed  CAS  Google Scholar 

  7. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341: 848–51

    Article  PubMed  CAS  Google Scholar 

  8. Mohan D, Mohandas E, Rajat R. Chloroquine psychosis: a chemical psychosis. J Natl Med Assoc 1981; 73: 1073–6

    PubMed  CAS  Google Scholar 

  9. Ragan E, Wilson R, Li F, et al. Psychotic symptoms in volunteers serving overseas. Lancet 1985; 2: 37

    Article  PubMed  CAS  Google Scholar 

  10. Umez-Eronini EM, Eronini EA. Chloroquine induced involuntary movements. BMJ 1977; 1: 945–6

    Article  PubMed  CAS  Google Scholar 

  11. Singh RPN, Sinha AKN. Neuropsychiatric toxicity of chloroquine. J Indian Med Assoc 1981; 77: 133–4

    PubMed  CAS  Google Scholar 

  12. Bhargava RK. Extrapyramidal syndrome following medication with some antimalarials [letter]. J Assoc Physicians India 1973; 21: 269

    Google Scholar 

  13. Singhi S, Singhi P, Singhi M. Chloroquine-induced involuntary movements. BMJ 1977; 2: 520

    Article  PubMed  CAS  Google Scholar 

  14. Achumba JI, Ette EI, Wilkinson TOA, et al. Chloroquine-induced acute dystonic reactions in the presence of metronidazole. Drug Intell Clin Pharm 1988; 22: 308–10

    PubMed  CAS  Google Scholar 

  15. Torrey EF. Chloroquine seizures. JAMA 1968; 204: 867–70

    Article  PubMed  CAS  Google Scholar 

  16. Oakley GP. The neurotoxicity of the halogenated hydroxy-quinolines. JAMA 1973; 225: 395–7

    Article  PubMed  Google Scholar 

  17. Fish DR, Espir MLE. Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. BMJ 1988; 297: 526–7

    Article  PubMed  CAS  Google Scholar 

  18. Fish DR, Espir MLE. Malaria prophylaxis and epilepsy. BMJ 1988; 297: 1267

    Article  Google Scholar 

  19. Froscher W, Hagele H. Verdacht auf anfallsfordernde Wirkung von chloroquin (Resochin®). Nervenarzt 1989; 60: 762–3

    PubMed  CAS  Google Scholar 

  20. Courtois X, Vincent F, Legoff F. Crises convulsives apres prophylaxie par chloroquine. Presse Med 1993; 22: 317

    Google Scholar 

  21. Kersley GD, Palin AG. Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet 1959; 2: 886–8

    Article  PubMed  CAS  Google Scholar 

  22. Akindele MO, Odejide AO. Amodiaquine-induced involuntary movements. BMJ 1976; 2: 214–5

    Article  PubMed  CAS  Google Scholar 

  23. Palmer K, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45(3): 430–75

    Article  PubMed  CAS  Google Scholar 

  24. Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 1989; 321: 1415–6

    Article  PubMed  CAS  Google Scholar 

  25. ter Kuile FO, Nosten F, Luxemburger C, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ. In press

  26. ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341: 1044–9

    Article  PubMed  Google Scholar 

  27. Bernard J, Le Camus J, Sarrouy J, et al. Encephalopathie toxique a la mefloquine. Presse Med 1987; 16: 1654–5

    PubMed  CAS  Google Scholar 

  28. Rouveix B, Bricaire F, Michon C, et al. Mefloquine and acute brain syndrome. Ann Intern Med 1989; 110: 577–8

    PubMed  CAS  Google Scholar 

  29. Stuiver PC, Ligthelm RJ, Goud TJLM. Acute psychosis after mefloquine. Lancet 1989; 2: 282

    Article  PubMed  CAS  Google Scholar 

  30. Lapras J, Vighetto A, Trillet M, et al. Trouble transitoire dememoire au decours d’un acces palustre. Presse Med 1989; 18: 776

    PubMed  CAS  Google Scholar 

  31. World Health Organization. Central nervous system reactions related to the antimalarial drug, mefloquine. WHO/MAL/89/1054. Geneva: World Health Organization, 1989

    Google Scholar 

  32. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am Soc Trop Med Hyg 1991; 45: 86–91

    CAS  Google Scholar 

  33. Sowunmi A, Salako LA, Oduola AMJ, et al. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg 1993; 87: 462–3

    Article  PubMed  CAS  Google Scholar 

  34. Luxemburger C, Nosten F, ter Kuile FO, et al. Mefloquine for multidrug-resistant malaria [letter]. Lancet 1991; 338: 1268

    Article  PubMed  CAS  Google Scholar 

  35. ter Kuile FO, Luxemburger C, Nosten F, et al. Serious neuropsychiatric adverse events following mefloquine treatment: evidence for a dose relationship? In: ter Kuile FO, editor. Mefloquine, halofantrine, and artesunate in the treatment of uncomplicated falciparum malaria in a multi-drug resistant area [PhD thesis], Amsterdam: University of Amsterdam, 1994: 173–82

    Google Scholar 

  36. World Health Organization. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985–1990). WHO/MAL/91.1063. Geneva: World Health Organization, 1991

    Google Scholar 

  37. Magnussen P, Bygbjerg IC. Treatment of Plasmodium falciparum malaria with mefloquine alone or in combination with IV quinine at the Department of Communicable and Tropical Diseases, Rigshospitalet, Copenhagen 1982–1988. Dan Med Bull 1990; 37: 563–4

    PubMed  CAS  Google Scholar 

  38. Chantavanich P, Looareesuwan S, White NJ, et al. Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. Am J Trop Med Hyg 1985; 34: 1028–36

    Google Scholar 

  39. Bjorkman AB. Acute psychosis following mefloquine prophylaxis [letter]. Lancet 1989; 2: 865

    Article  PubMed  CAS  Google Scholar 

  40. Bern JL, Kerr L, Sturchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167–79

    Google Scholar 

  41. Boudreau EF, Schuster B, Sanchez J, et al. Tolerance of prophylactic Lariam® regimens [abstract TuS6-3]. 13th International Congress for Tropical Medicine and Malaria. 1992 Nov 29–Dec 4: Jomtien, Pattaya, Thailand, 150

  42. Boland ME, Brennard Roper SM, Henry JA. Complications of quinine poisoning. Lancet 1985; 1: 384–5

    Article  PubMed  CAS  Google Scholar 

  43. Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med 1985; 54(214): 125–31

    PubMed  CAS  Google Scholar 

  44. Rheeder P, Sieling WL. Acute persistent quinine-induced blindness. South Afr Med J 1991; 79: 563–4

    CAS  Google Scholar 

  45. Roche RJ, Silamut K, Pukrittayakamee S, et al. Quinine induces reversible high-tone hearing loss. Br J Clin Pharmacol 1990; 29: 780–2

    Article  PubMed  CAS  Google Scholar 

  46. Winstanley P, Newton C, Watkins W, et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Trans R Soc Trop Med Hyg 1993; 87: 201–6

    Article  PubMed  CAS  Google Scholar 

  47. White NJ. Drug treatment and prevention in malaria. Eur J Clin Pharmacol 1988; 34: 1–14

    Article  PubMed  CAS  Google Scholar 

  48. Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. BMJ 1987; 294: 1001–2

    Article  PubMed  CAS  Google Scholar 

  49. Green R. Toxic effects associated with the use of atebrin. Malays Med J 1934; 1: 22–33

    Google Scholar 

  50. Hoops AL. The advantages of atebrin in the treatment of malaria amongst controlled labour forces in Malaya. Trans R Soc Trop Med Hyg 1935; 29: 249–59

    Article  Google Scholar 

  51. Wolfe MS. Current concepts in parasitology: giardiasis. N Engl J Med 1978; 298: 319–21

    Article  PubMed  CAS  Google Scholar 

  52. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049–55

    Article  PubMed  CAS  Google Scholar 

  53. Brewer TG, Peggins JO, Grate SJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 1994; 88(Suppl. 1): 33–6

    Article  CAS  Google Scholar 

  54. Petras JM, Kyle DE, Ngampochjana M, et al. Arteether induced brainstem injury in macaca mulatta [abstract 18]. In: Program and abstracts of the 43rd annual meeting of the American Society of Tropical Medicine and Hygiene: 1994 Nov 13–17; Cincinnati, Ohio. Am J Trop Med Hyg 1994; 51: 100

    Google Scholar 

  55. Brewer TG, Petras JM, Peggins JO, et al. Differential neurotoxicity of artemisinin analogs in an in vivo model [abstract 413]. Program and abstracts of the 43rd annual meeting of the American Society of Tropical Medicine and Hygiene; 1993 Oct 31–Nov 4; Atlanta (GA). Am J Trop Med Hyg 1993; 49(3): 292

    Google Scholar 

  56. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603–8

    Article  PubMed  CAS  Google Scholar 

  57. Nosten F. Artemisinin: large community studies. Trans R Soc Trop Med Hyg 1994; 88(Suppl. 1): 45–6

    Article  Google Scholar 

  58. Akinyanju O, Goddell JC, Ahmed I. Pyrimethamine poisoning. BMJ 1973; 4: 147–8

    Article  PubMed  CAS  Google Scholar 

  59. Elmalem J, Poulet B, Gamier R, et al. Les accidents grave lors de la prescription de pyrimethamine chez les nourrissons traites pour une toxoplasmose. Therapie 1985; 40: 357–9

    PubMed  CAS  Google Scholar 

  60. Reynolds JEF, editor. Martindale: the extrapharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989: 393–411

    Google Scholar 

  61. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ 1991; 69(3): 297–304

    PubMed  CAS  Google Scholar 

  62. Bioland PB, Redd SC, Kazembe P, et al. Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 1991; 337: 518–20

    Article  Google Scholar 

  63. Kremer I, Ritz R, Brunner F. Aseptic meningitis as an adverse effect of co-trimoxazole [letter]. N Engl J Med 1983; 308: 1481

    PubMed  CAS  Google Scholar 

  64. Haas EJ. Trimethoprim-sulfamethoxazole: another cause of recurrent meningitis [letter]. JAMA 1984; 252: 346

    Article  PubMed  CAS  Google Scholar 

  65. Derbes SJ. Trimethoprim induced aseptic meningitis. JAMA 1984; 252: 2865

    Article  PubMed  CAS  Google Scholar 

  66. Gutman LT. The use of trimethoprim-sulfamethoxazole in children: a review of adverse reactions and indications. Pediatr Infect Dis 1984; 3(4): 349–57

    Article  PubMed  CAS  Google Scholar 

  67. Volden G. Peripheral neuropathy: a side effect of sulphones. BMJ 1977; 1: 1193

    Article  PubMed  CAS  Google Scholar 

  68. Schvartsman S. Sulfone methemaglobinemia. Clin Toxicol 1979; 15: 468

    Google Scholar 

  69. Tester-Dalderup CBM. Antiprotozoal drugs. In: Dukes MNG, editor. Meylers side effects of drugs. 11th ed. Amsterdam: Elsevier Science Publishers, 1988: 581–602

    Google Scholar 

  70. Hoigne R, Keller H, Sonntag R. Penicillins, cephalosporins and tetracyclines. In: Dukes MNG, editor. Meylers side effects of drugs, 11th ed. Amsterdam: Elsevier Science Publishers, 1988: 521–42

    Google Scholar 

  71. Walters BNJ, Gubbay SS. Tetracycline and benign intracranial hypertension: report of five cases. BMJ 1981; 282: 19–20

    Article  PubMed  CAS  Google Scholar 

  72. Rodrigo C, Mayol L, Sanchez de Toledo J, et al. Doxiciclina y toxicidad vestibular. Med Clin 1983; 81: 649

    CAS  Google Scholar 

  73. Horton RJ, Parr SN, Bokor LC. Clinical experience with halofantrine in the treatment of malaria. Drugs Exp Clin Res 1990; 16: 497–503

    PubMed  CAS  Google Scholar 

  74. Poblot F, Becq-Giraudon B, Breux J-P, et al. Convulsive seizures during treatment with halofantrine. Bull Fr Parasitol Soc 1990; 8(2): 445

    Google Scholar 

  75. Spencer CM, Goa KL. Atovaquone: a review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. In press

  76. Sowunmi A. Psychosis after cerebral malaria in children. J Natl Med Assoc 1993; 85: 695–6

    PubMed  CAS  Google Scholar 

  77. Phillips-Howard PA. Regulation of drug use and post-registration surveillance. Trans R Soc Trop Med Hyg 1994; 88(Suppl. 1): 59–62

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Malaria Unit, Division of Control of Tropical Diseases, World Health Organization, Geneva, Switzerland

    Penelope A. Phillips-Howard

  2. Unit of Infectious Diseases, AIDS and Tropical Medicine, Academic Medical Centre, F4-222, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Feiko O. ter Kuile

Authors
  1. Penelope A. Phillips-Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feiko O. ter Kuile
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phillips-Howard, P.A., ter Kuile, F.O. CNS Adverse Events Associated With Antimalarial Agents. Drug-Safety 12, 370–383 (1995). https://doi.org/10.2165/00002018-199512060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199512060-00003

Keywords

Search

Navigation